Survival 96.6% vs 91.2% Significantly reduced likelihood (69%) of progression to ventilation in higher severity cohort Significantly increased likelihood (88%) of shorter time to recovery or discharge in higher severity cohort Clinical evidence of anti-viral mechanism of action Preclinical analysis highlights bemcentinib’s potential against COVID-19 variants Bergen, Norway, 12 July 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company … Read more
Bergen, Norway, 10 July 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that preclinical data from a study investigating the anti-tumor efficacy of BerGenBio’s AXL-inhibitors bemcentinib and tilvestamab in renal cell carcinoma (RCC) was presented at the European Association of Urology 2021 virtual congress. Data from the study, conducted … Read more
Bergen, Norway, 29 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that its late-breaking abstract, outlining Phase II clinical trial of bemcentinib, a first-in-class selective oral AXL inhibitor, in hospitalised COVID-19 patients has been published at the European Congress of Clinical Microbiology & … Read more
Bergen, Norway, 28 June 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that Prof. Hani Gabra MD PhD, Chief Medical Officer of BerGenBio, will deliver a virtual presentation at the 4th Annual Next Gen Immuno-Oncology Congress, which is taking place virtually from 28 … Read more
Bergen, Norway, 16 June 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 11 June 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to … Read more
Bergen, Norway, 11 June 2021 The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, today resolved to increase the Company’s share capital by NOK 7,500 by issuance … Read more
Lovende oppdaterte foreløpige overlevelsesdata, en dobling sammenlignet med standardbehandling rapportert for AML pasienter med tilbakefall Bergen, Norge, 11. juni 2021 - BerGenBio ASA (OSE:BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, vil presentere oppdaterte foreløpige overlevelsesdata fra den pågående fase-II studien av bemcentinib (BGBC003) i kombinasjon med … Read more
Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients Bergen, Norway, 11 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present updated preliminary survival data from the ongoing Phase II study of bemcentinib (BGBC003) in combination with low dose … Read more
Bergen, Norway, 10 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that an analysis of its Phase II clinical trial of bemcentinib, a first-in-class selective oral AXL inhibitor, in hospitalised COVID-19 patients has been selected as a late-breaking abstract at the European Congress … Read more
Dette er den første regulatoriske anerkjennelsen av AXL-positive pasienter som en målrettet pasientpopulasjon. Bergen, Norge, 8. juni 2021 - BerGenBio ASA (OSE:BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, kunngjør i dag at det amerikanske legemiddelverket (FDA) har gitt fast track status for bemcentinib i kombinasjon … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.